Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous platelet-rich plasma (PRP) combined with Spongostan is an investigational biologic-device combination used intraoperatively during tympanoplasty. PRP is a concentrated source of autologous platelets and growth factors, including platelet-derived growth factor (PDGF), transforming growth factor beta (TGF-β), and vascular endothelial growth factor (VEGF), which promote tissue regeneration and wound healing. Spongostan, an absorbable gelatin sponge manufactured by Ethicon (Johnson & Johnson), acts as a resorbable scaffold to deliver the PRP to the surgical site and stabilize the graft. This combination is primarily studied for improving graft success rates and audiological outcomes in patients with chronic otitis media and tympanic membrane perforation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous platelet-rich plasma + spongostan.